Provided By GlobeNewswire
Last update: Feb 28, 2025
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced its attendance and presentations at upcoming investor conferences.
Read more at globenewswire.comNASDAQ:MOLN (7/23/2025, 8:00:00 PM)
3.895
+0.16 (+4.37%)
Find more stocks in the Stock Screener